Purple Biotech (PPBT) Receivables (2019 - 2025)
Purple Biotech (PPBT) posted quarterly Receivables of $326000.0 for Q2 2025, up 1381.82% year-over-year from $22000.0 in Q2 2024, and down 30.49% quarter-over-quarter from $469000.0 in Q1 2025.
Purple Biotech (PPBT) Receivables (2019 - 2025) Analysis & Trends
Purple Biotech (PPBT) has reported Receivables for 7 consecutive years, with $326000.0 the latest figure, recorded in Q2 2025.
- In Q2 2025, Receivables rose 1381.82% year-over-year to $326000.0; the TTM figure through Jun 2025 stood at $326000.0 (up 1381.82% YoY), while the FY2024 annual figure was $276000.0, up 272.97% from the prior year.
- Receivables slipped to $326000.0 in Q2 2025 per PPBT's latest filing, from $469000.0 in the prior quarter.
- Across five years, Receivables topped out at $500000.0 in Q1 2021 and bottomed at $14000.0 in Q3 2024.
- Historically, Receivables has averaged $264611.1 across 5 years, with a median of $234500.0 in 2021.
- Annual changes were most pronounced in 2024 — Receivables sank 94.56% — and 2025, when it surged 2133.33%.
- Purple Biotech's Receivables stood at $193000.0 in 2021, then jumped by 123.32% to $431000.0 in 2022, then slumped by 82.83% to $74000.0 in 2023, then jumped by 272.97% to $276000.0 in 2024, then increased by 18.12% to $326000.0 in 2025.
- Business Quant data shows PPBT's Receivables at $326000.0 in Q2 2025, $469000.0 in Q1 2025, and $276000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 912.74 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 215.33 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.09 Bn |
| 10 | Purple Biotech | 133.62 | 133.62 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 326,000.00 |
| Mar 31, 2025 | 469,000.00 |
| Dec 31, 2024 | 276,000.00 |
| Sep 30, 2024 | 14,000.00 |
| Jun 30, 2024 | 22,000.00 |
| Mar 31, 2024 | 21,000.00 |
| Dec 31, 2023 | 74,000.00 |
| Sep 30, 2023 | 138,000.00 |
| Jun 30, 2023 | 352,000.00 |
| Mar 31, 2023 | 386,000.00 |
| Dec 31, 2022 | 431,000.00 |
| Sep 30, 2022 | 187,000.00 |
| Jun 30, 2022 | 187,000.00 |
| Mar 31, 2022 | 187,000.00 |
| Dec 31, 2021 | 193,000.00 |
| Sep 30, 2021 | 500,000.00 |
| Jun 30, 2021 | 500,000.00 |
| Mar 31, 2021 | 500,000.00 |
| Dec 31, 2020 | 500,000.00 |
| Jun 30, 2020 | 1.00 Mn |